Dai-ichi Life Insurance Company’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.86M | Hold |
4,579
| – | – | 0.07% | 236 |
|
|
2026
Q1 | $3.54M | Sell |
4,579
-52
| -1% | -$39.8K | 0.1% | 187 |
|
|
2025
Q4 | $3.57M | Sell |
4,631
-148
| -3% | -$101K | 0.09% | 196 |
|
|
2025
Q3 | $2.69M | Buy |
4,779
+1,300
| +37% | +$735K | 0.07% | 229 |
|
|
2025
Q2 | $1.83M | Sell |
3,479
-5,949
| -63% | -$3.32M | 0.05% | 274 |
|
|
2025
Q1 | $5.98M | Sell |
9,428
-494
| -5% | -$340K | 0.17% | 129 |
|
|
2024
Q4 | $7.07M | Sell |
9,922
-2,470
| -20% | -$2.07M | 0.2% | 115 |
|
|
2024
Q3 | $13M | Sell |
12,392
-2,383
| -16% | -$2.65M | 0.33% | 73 |
|
|
2024
Q2 | $15.5M | Buy |
14,775
+111
| +0.8% | +$108K | 0.38% | 66 |
|
|
2024
Q1 | $14.1M | Sell |
14,664
-3,433
| -19% | -$3.26M | 0.32% | 73 |
|
|
2023
Q4 | $15.9M | Buy |
18,097
+750
| +4% | +$618K | 0.33% | 71 |
|
|
2023
Q3 | $14.3M | Buy |
17,347
+79
| +0.5% | +$62.1K | 0.31% | 73 |
|
|
2023
Q2 | $12.4M | Sell |
17,268
-14,794
| -46% | -$11.4M | 0.26% | 80 |
|
|
2023
Q1 | $26.3M | Buy |
32,062
+1,008
| +3% | +$760K | 0.58% | 37 |
|
|
2022
Q4 | $22.4M | Buy |
31,054
+672
| +2% | +$496K | 0.52% | 39 |
|
|
2022
Q3 | $20.9M | Buy |
30,382
+1,000
| +3% | +$629K | 0.52% | 40 |
|
|
2022
Q2 | $17.4M | Sell |
29,382
-13,018
| -31% | -$8.46M | 0.39% | 54 |
|
|
2022
Q1 | $29.6M | Sell |
42,400
-1,978
| -4% | -$1.25M | 0.47% | 43 |
|
|
2021
Q4 | $28M | Hold |
44,378
| – | – | 0.36% | 57 |
|
|
2021
Q3 | $26.9M | Buy |
44,378
+1,284
| +3% | +$797K | 0.35% | 53 |
|
|
2021
Q2 | $24.1M | Buy |
43,094
+12,817
| +42% | +$6.49M | 0.3% | 61 |
|
|
2021
Q1 | $14.3M | Sell |
30,277
-1,723
| -5% | -$839K | 0.2% | 89 |
|
|
2020
Q4 | $15.5M | Buy |
32,000
+8,340
| +35% | +$4.5M | 0.22% | 79 |
|
|
2020
Q3 | $13.2M | Buy |
23,660
+4,544
| +24% | +$2.76M | 0.24% | 80 |
|
|
2020
Q2 | $11.9M | Buy |
19,116
+9,803
| +105% | +$5.56M | 0.27% | 69 |
|
|
2020
Q1 | $4.55M | Buy |
9,313
+4,500
| +93% | +$1.86M | 0.17% | 135 |
|
|
2019
Q4 | $1.81M | Sell |
4,813
-5,000
| -51% | -$1.68M | 0.04% | 340 |
|
|
2019
Q3 | $2.72M | Hold |
9,813
| – | – | 0.07% | 278 |
|
|
2019
Q2 | $3.07M | Hold |
9,813
| – | – | 0.07% | 256 |
|
|
2019
Q1 | $4.03M | Buy |
9,813
+113
| +1% | +$46.5K | 0.1% | 213 |
|
|
2018
Q4 | $3.62M | Hold |
9,700
| – | – | 0.1% | 218 |
|
|
2018
Q3 | $3.92M | Sell |
9,700
-29
| -0.3% | -$11K | 0.08% | 218 |
|
|
2018
Q2 | $3.36M | Sell |
9,729
-1,416
| -13% | -$443K | 0.08% | 247 |
|
|
2018
Q1 | $3.84M | Hold |
11,145
| – | – | 0.08% | 224 |
|
|
2017
Q4 | $4.19M | Hold |
11,145
| – | – | 0.08% | 215 |
|
|
2017
Q3 | $4.98M | Sell |
11,145
-6,000
| -35% | -$2.86M | 0.11% | 188 |
|
|
2017
Q2 | $8.42M | Buy |
17,145
+1,001
| +6% | +$438K | 0.19% | 115 |
|
|
2017
Q1 | $6.26M | Buy |
16,144
+8,000
| +98% | +$2.97M | 0.17% | 143 |
|
|
2016
Q4 | $2.99M | Buy |
+8,144
| New | +$3.1M | 0.09% | 235 |
|
Other funds holding REGN
Dai-ichi Life Insurance Company's REGN Position: Q2 2026 in Review
Dai-ichi Life Insurance Company held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 4,579 shares worth $2.86M. The position accounts for 0.07% of the portfolio, ranked #236.
Dai-ichi Life Insurance Company first reported a position in REGN in Q4 2016 and has held it in 39 quarters since. The position peaked at $29.6M in Q1 2022. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Dai-ichi Life Insurance Company held 4,579 shares of Regeneron Pharmaceuticals worth $2.86M as of Q2 2026.
- Dai-ichi Life Insurance Company left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
- Regeneron Pharmaceuticals made up 0.07% of Dai-ichi Life Insurance Company's portfolio in Q2 2026, its #236 holding.
- Dai-ichi Life Insurance Company first reported a position in Regeneron Pharmaceuticals in Q4 2016 and has held it in 39 quarters since.
- Dai-ichi Life Insurance Company's Regeneron Pharmaceuticals position peaked at $29.6M in Q1 2022.
- 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Dai-ichi Life Insurance Company's 13F filing for Q2 2026, filed 12 Aug 2026.